[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 119
1. Lin PP, Pino ED, Normand AN, Deavers MT, Cannon CP, Ballo MT, Pisters PW, Pollock RE, Lewis VO, Zagars GK, Yasko AW: Periosteal margin in soft-tissue sarcoma. Cancer; 2007 Feb 1;109(3):598-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periosteal margin in soft-tissue sarcoma.
  • BACKGROUND: Soft-tissue sarcomas frequently rest in contact with bone.
  • METHODS: Fifty patients with soft-tissue sarcomas abutting bone were treated at a single institution between 1990 and 2004.
  • In 11 cases a composite resection of bone and soft tissue was performed.
  • In 39 cases the excision involved only soft tissue.
  • Local recurrence in the soft tissues developed in 8 of 50 (16%) patients.
  • The recurrent tumor resided against the region of previous bone contact in 1 of 8 cases.
  • There was no statistically significant difference in local recurrence between patients who had composite bone resection and patients who had soft-tissue resection only (P = .87).
  • Composite bone and soft-tissue resections are indicated primarily for frank bone invasion.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Periosteum / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate


2. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG: Retroperitoneal soft tissue sarcoma. Cancer; 2005 Aug 15;104(4):669-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal soft tissue sarcoma.
  • The objective of the current study was to define the optimal treatment for patients with retroperitoneal soft tissue sarcomas (RPS).
  • The 5-year survival rate was approximately 50%, and deaths due to recurrent RPS continued to occur after 5 years.
  • Most patients experienced recurrent disease after surgery, and the most common site of failure was local.
  • [MeSH-major] Digestive System Surgical Procedures. Retroperitoneal Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003776.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


3. Canter RJ, Qin LX, Ferrone CR, Maki RG, Singer S, Brennan MF: Why do patients with low-grade soft tissue sarcoma die? Ann Surg Oncol; 2008 Dec;15(12):3550-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Why do patients with low-grade soft tissue sarcoma die?
  • INTRODUCTION: The patterns of failure and mechanisms of sarcoma-specific death are poorly characterized among the minority of patients with low-grade soft tissue sarcoma (STS) who succumb to disease.
  • Overall, 105 patients (58%) died from locally recurrent disease (DOLR), and 59 (32%) died from distant disease (DODR).
  • In 17 patients (9%), the mechanism of sarcoma-related death could not be verified.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Jul 1;62(1):184-93 [3383114.001]
  • [Cites] Biometrics. 1978 Dec;34(4):541-54 [373811.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] World J Surg. 1988 Jun;12(3):326-31 [3400243.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1317-29 [1634922.001]
  • [Cites] Arch Surg. 1993 Dec;128(12):1336-43 [8250705.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):165-73 [8129487.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] Cancer. 1996 May 1;77(9):1823-30 [8646680.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):402-8 [15578681.001]
  • [Cites] Immunol Res. 2005;32(1-3):231-45 [16106075.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Histopathology. 2006 Jan;48(1):42-50 [16359536.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):791-6 [11821462.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Cancer. 2003 May 15;97(10):2530-43 [12733153.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):432-40 [12734093.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):78-84 [14699038.001]
  • [Cites] Biometrics. 1979 Mar;35(1):25-39 [497336.001]
  • (PMID = 18830667.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA047179-09; United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA 047179; United States / NCI NIH HHS / CA / P01 CA047179-09
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS75337; NLM/ PMC2605207
  •  go-up   go-down


Advertisement
4. Liebl LS, Elson F, Quaas A, Gawad KA, Izbicki JR: Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res; 2007 Jul-Aug;27(4C):2897-902
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma.
  • BACKGROUND: Pulmonary metastasectomy in soft tissue sarcoma (STS) can lead to long-term survival.
  • The aim of our study was to report on prognostic factors and the value of repeat resection in recurrent disease.
  • CONCLUSION: Patients with repeat resections due to recurrent metastasis show a significantly better prognosis than those with only one resection.
  • Thus, lacking randomised controlled data of the natural course of patients with unresected lung metastases to compare these results, metastasectomy in STS patients is also recommended in recurrent disease.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. Middle Aged. Neoplasm Staging. Reoperation. Survival Rate. Treatment Outcome


5. Goel V, Goel A, Gupta N, Bhamre S: Flap reconstruction and interstitial brachytherapy in nonextremity soft tissue sarcoma. J Cancer Res Ther; 2007 Apr-Jun;3(2):105-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flap reconstruction and interstitial brachytherapy in nonextremity soft tissue sarcoma.
  • Radiotherapy is an integral component of management of high-grade soft tissue sarcomas.
  • We preset our initial experience with interstitial brachytherapy in two patients of recurrent high-grade non-extremity sarcomas treated with surgical excision and soft tissue reconstruction of surgical defect.
  • [MeSH-major] Brachytherapy. Sarcoma / therapy. Scapula. Surgical Flaps
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998734.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


6. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, Eary JF: Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer; 2005 Jan 15;103(2):339-48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
  • BACKGROUND: Patients with high-grade soft tissue sarcomas are at high risk of developing local disease recurrence and metastatic disease.
  • Patients whose tumors had a >/= 40% decline in the SUVmax in response to chemotherapy were at a significantly lower risk of recurrent disease and death after complete resection and adjuvant radiotherapy.
  • CONCLUSIONS: The FDG-PET scan was found to be a useful method with which to predict the outcomes of patients with high-grade extremity soft tissue sarcomas treated with chemotherapy.
  • The FDG-PET scan showed promise as a tool to identify the patients with sarcoma who are most likely to benefit from chemotherapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Positron-Emission Tomography. Sarcoma / drug therapy. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Lower Extremity. Male. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Neoplasm Staging. Orthopedic Procedures / methods. Probability. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome. Upper Extremity

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15578712.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA65537; United States / NCI NIH HHS / CA / CA76930; United States / NCI NIH HHS / CA / CA87721
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Indelicato DJ, Meadows K, Gibbs CP Jr, Morris CG, Scarborough MT, Zlotecki RA: Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):267-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma.
  • PURPOSE: The management of isolated local recurrence of soft-tissue sarcoma is therapeutically complex, and functional conservative management is preferable to radical or amputative salvage surgery.
  • This study reviews the University of Florida experience using conservative resection and reirradiation to manage isolated local recurrences of soft-tissue sarcoma.
  • CONCLUSIONS: Salvage therapy for management of locally recurrent soft-tissue sarcoma is challenging, and the effects of reoperation and reirradiation can be severe.
  • [MeSH-major] Sarcoma / radiotherapy. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707824.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Krempien R, Roeder F, Oertel S, Weitz J, Hensley FW, Timke C, Funk A, Lindel K, Harms W, Buchler MW, Debus J, Treiber M: Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):773-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma.
  • PURPOSE: This study assesses the long-term outcome of patients with retroperitoneal soft-tissue sarcomas treated by maximal resection in combination with intraoperative electron-beam therapy (IOERT) and postoperative external-beam radiotherapy.
  • METHODS AND MATERIALS: From 1991 to 2004, 67 patients were treated with curative intent for primary (n = 26) or recurrent (n = 41) retroperitoneal soft-tissue sarcoma.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Intraoperative Period. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682152.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lehnert T, Cardona S, Hinz U, Willeke F, Mechtersheimer G, Treiber M, Herfarth C, Buechler MW, Schwarzbach MH: Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol; 2009 Sep;35(9):986-93
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival.
  • AIM: To evaluate local control for long-term prognosis in retroperitoneal soft-tissue sarcoma (primary tumors (PT) and local recurrence (LR)).
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Retroperitoneal Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138832.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Chiappa A, Zbar AP, Bertani E, Biffi R, Luca F, Crotti C, Testori A, Lazzaro G, De Pas T, Pace U, Andreoni B: Primary and recurrent retroperitoneal soft tissue sarcoma: prognostic factors affecting survival. J Surg Oncol; 2006 May 1;93(6):456-63
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and recurrent retroperitoneal soft tissue sarcoma: prognostic factors affecting survival.
  • BACKGROUND AND OBJECTIVES: To analyze treatment and survival in 34 patients (28 resected) with primary or recurrent retroperitoneal sarcoma (RPS).
  • RESULTS: Twenty-eight out of 34 patients (82%) (15 were affected by primary RPS, and 13 by recurrent RPS), underwent surgical exploration.
  • CONCLUSIONS: An aggressive surgical approach in both primary and recurrent RPS is associated with long-term survival.
  • [MeSH-major] Neoplasm Recurrence, Local / mortality. Retroperitoneal Neoplasms / mortality. Retroperitoneal Neoplasms / surgery. Sarcoma / mortality. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Survivors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615149.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Lans TE, Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM: Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol; 2005 May;12(5):406-11
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
  • BACKGROUND: Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradiated area can usually be managed only by amputation.
  • Out of 342 TNF-based ILPs between 1991 and 2003, 30 ILPs were performed in 26 patients with recurrent STS in the irradiated field after prior surgery and radiotherapy.
  • CONCLUSIONS: TNF-based ILP can avoid amputations in most patients with recurrent extremity STS in a prior operated and irradiated field.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Limb Salvage / methods. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arm. Combined Modality Therapy. Female. Humans. Leg. Male. Middle Aged

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915375.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


12. Hui AC, Ngan SY, Wong K, Powell G, Choong PF: Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience. Eur J Surg Oncol; 2006 Dec;32(10):1159-64
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience.
  • AIM: Radiotherapy has been shown to improve local control in combination with limb-sparing or conservative surgery in the management of localised soft tissue sarcoma.
  • METHODS: Consecutive patients with localised extremity or truncal soft tissue sarcoma who presented between January 1996 and December 2000 and treated with preoperative radiotherapy followed by limb-sparing surgery were reviewed.
  • Patients with recurrent disease or metastatic disease at diagnosis and patients below the age of 16years were excluded.
  • CONCLUSION: Preoperative radiotherapy followed by surgery provides effective local control in the management of soft tissue sarcoma.
  • [MeSH-major] Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Radiation Injuries. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765559.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Tran PT, Hara W, Su Z, Lin HJ, Bendapudi PK, Norton J, Teng N, King CR, Kapp DS: Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. Int J Radiat Oncol Biol Phys; 2008 Nov 15;72(4):1146-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults.
  • PURPOSE: To analyze the outcomes of and identify prognostic factors for patients treated with surgery and intraoperative radiotherapy (IORT) for locally advanced and recurrent soft-tissue sarcoma in adults from a single institution.
  • Seventy percent of patients had recurrent disease failing prior surgery (70%) and/or radiation (32%).
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. California / epidemiology. Humans. Incidence. Intraoperative Care / methods. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394818.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Pink D, Rahm J, Schoeler D, Schoenknecht TM, Reichardt P: Activity of paclitaxel in radiation induced and other secondary angiosarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):10578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10578 Background: Angiosarcomas (AS) represent 1-2% of adult soft tissue sarcomas and can arise anywhere in the body.
  • All 14 patients with recurrent/metastatic disease were treated with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Jakob J, Wenz F, Dinter DJ, Ströbel P, Hohenberger P: Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2009 Nov 1;75(3):810-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
  • PURPOSE: To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS).
  • PATIENTS AND METHODS: A cohort of 15 consecutive patients with nonmetastasized, primary high-grade or locally recurrent Stage III (n = 14) or IIb (n = 1) STS not amenable to surgical resection without significant organ or extremity function loss was prospectively investigated.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Radiotherapy, Intensity-Modulated. Sarcoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Nausea / etiology. Postoperative Complications. Prospective Studies. Radiation Injuries / etiology. Radiotherapy Dosage. Remission Induction. Tumor Burden. Vomiting / etiology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


16. Eilber FC, Brennan MF, Riedel E, Alektiar KM, Antonescu CR, Singer S: Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas. Ann Surg Oncol; 2005 Mar;12(3):228-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas.
  • BACKGROUND: Factors prognostic for survival in patients with locally recurrent extremity soft tissue sarcomas (STS) are poorly defined, thus making it difficult to identify high-risk patients who may benefit from adjuvant therapy.
  • CONCLUSIONS: Histological grade, local recurrence size, and local recurrence-free interval are independently predictive of survival in patients with locally recurrent extremity STS.
  • [MeSH-major] Extremities. Neoplasm Recurrence, Local. Sarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Lower Extremity / pathology. Lower Extremity / surgery. Male. Middle Aged. Prognosis. Risk Factors. Upper Extremity / pathology. Upper Extremity / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827815.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA47179
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


17. Rehders A, Peiper M, Stoecklein NH, Alexander A, Boelke E, Knoefel WT, Rogiers X: Hepatic metastasectomy for soft-tissue sarcomas: is it justified? World J Surg; 2009 Jan;33(1):111-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastasectomy for soft-tissue sarcomas: is it justified?
  • BACKGROUND: Except for patients with gastrointestinal stromal tumors (GIST), systemic chemotherapy in patients with liver metastasis of soft-tissue sarcoma (STS) is not effective.
  • Repeated resection for recurrent tumor was performed in eight patients, which yielded a median survival of 76 months.
  • [MeSH-major] Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Neoplasm Staging. Reoperation. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949511.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Chen F, Fujinaga T, Sato K, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H: Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma. Eur J Surg Oncol; 2009 Jun;35(6):660-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma.
  • BACKGROUND: Resection for pulmonary metastasis from soft tissue sarcomas is an accepted method for treatment, but it is still debatable which patients will benefit from surgical intervention.
  • METHODS: Between 1990 and 2007, 23 patients with pulmonary metastases from soft tissue sarcomas underwent complete pulmonary resection.
  • In addition, repeat metastasectomy for recurrent pulmonary metastasis also provided a favorable overall survival (P=0.041).
  • CONCLUSIONS: Our data suggested that patients most likely to benefit from pulmonary metastasectomy for soft tissue sarcoma have no tumor recurrence before pulmonary metastasis.
  • Furthermore, patients with repeat metastasectomy for recurrent pulmonary metastasis also presented a significantly longer survival.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Pneumonectomy / mortality. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774675.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Rehders A, Hosch SB, Scheunemann P, Stoecklein NH, Knoefel WT, Peiper M: Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. Arch Surg; 2007 Jan;142(1):70-5; discission 76
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit of surgical treatment of lung metastasis in soft tissue sarcoma.
  • HYPOTHESIS: Patients with pulmonary metastatic soft tissue sarcoma benefit from resection, with long-term cure possible.
  • PATIENTS: Between January 1, 1991, and December 31, 2002, 61 patients (33 men and 28 women; median age at initial diagnosis, 42 years [age range, 18-74 years]) were surgically treated for pulmonary metastases of soft tissue sarcoma at University Hospital, Hamburg-Eppendorf, Germany.
  • CONCLUSIONS: Patients with lung metastasis from soft tissue sarcomas benefit from surgical excision.
  • Long-term survival is possible even when recurrent pulmonary disease is resected.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Histiocytoma / secondary. Histiocytoma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Sternum / surgery. Survival Analysis. Thoracotomy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224503.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F: Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer; 2008 Jun;50(6):1147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma.
  • BACKGROUND: Recent technical advances in CT imaging and data processing have improved the ability to detect small pulmonary nodules in children with bone and soft-tissue sarcoma undergoing radiologic imaging of the chest.
  • PROCEDURE: We retrospectively studied medical records and CT chest scans at initial diagnosis of 210 children and young adults presenting to a single pediatric tertiary care hospital specialized in oncology for evaluation of bone or soft-tissue sarcoma.
  • Having more than three nodules and a bilateral distribution were associated with histology-proven metastasis (P = 0.002 and P = 0.011, respectively) and an increased frequency of recurrent or progressive metastatic disease in the lung (P < 0.001 and P = 0.023, respectively).
  • CONCLUSIONS: Pulmonary nodules were commonly detected during the initial evaluation of pediatric cases of sarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Radiography, Thoracic. Sarcoma / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Solitary Pulmonary Nodule / radiography

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18300316.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, Hunt KK, Patel SR, Trent JC, Beddar S, Pisters PW: Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):158-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment.
  • PURPOSE: To evaluate the clinical outcomes of patients with localized retroperitoneal soft tissue sarcoma (STS) treated with complete surgical resection and radiation.
  • Multivariate analysis also indicated an inferior 5-year LC rate for patients presenting with recurrent disease, positive or uncertain resection margins, and age greater than 65 years.
  • [MeSH-major] Retroperitoneal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / surgery. Sarcoma / radiotherapy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084545.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 06294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


22. Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, Gilles L, Lebedinsky C, Elsayed YA, Le Cesne A: Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res; 2008 Oct 15;14(20):6656-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
  • PURPOSE: To determine the dose of trabectedin plus doxorubicin with granulocyte colony-stimulating factor support associated with manageable neutropenia and acceptable dose-limiting toxicities (DLT) in patients with recurrent or persistent soft-tissue sarcoma.
  • CONCLUSION: The combination of doxorubicin 60 mg/m(2) followed by trabectedin 1.1 mg/m(2) every 21 days is safe and active in patients with soft-tissue sarcoma.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5484-92 [16110008.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1867-74 [15774779.001]
  • [Cites] Cancer Radiother. 2006 Jun;10(4):185-207 [16917992.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):231-42 [11234874.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1256-65 [11230466.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):583-8 [11304695.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):870-7 [11313175.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3251-7 [11595721.001]
  • [Cites] Chem Biol. 2001 Dec;8(12):1151-60 [11755394.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):75-85 [11801542.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):832-40 [12910529.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Cancer. 1973 Jul;32(1):1-8 [4716773.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Biochemistry. 1996 Oct 15;35(41):13303-9 [8873596.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):981-7 [9818072.001]
  • [Cites] J Med Chem. 1999 Jul 15;42(14):2493-7 [10411470.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):576-84 [15659504.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4 [10841573.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1610-4 [16736024.001]
  • (PMID = 18927308.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927; None / None / / P30 CA006927-46; United States / NCI NIH HHS / CA / P30 CA006927-46
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS113333; NLM/ PMC2777645
  •  go-up   go-down


23. Mierzwa ML, McCluskey CM, Barrett WL, Lowy A, Sussman J, Sorger J: Interstitial brachytherapy for soft tissue sarcoma: A single institution experience. Brachytherapy; 2007 Oct-Dec;6(4):298-303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial brachytherapy for soft tissue sarcoma: A single institution experience.
  • PURPOSE: Soft tissue sarcomas (STSs) are an uncommon, histologically diverse group of malignancies, which are primarily treated with surgery.
  • METHODS AND MATERIALS: Forty-three patients were treated from 1997 to 2005 with adjuvant BTX for primary or recurrent STS.
  • Thirty-four patients were treated for primary and nine for recurrent disease in locations including upper and lower extremity, pelvis, superficial trunk, and retroperitoneum.
  • No patient with low-grade sarcoma developed distant metastasis.
  • [MeSH-major] Brachytherapy / methods. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17959424.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Koppert LB, van Geel AN, Lans TE, van der Pol C, van Coevorden F, Wouters MW: Sternal resection for sarcoma, recurrent breast cancer, and radiation-induced necrosis. Ann Thorac Surg; 2010 Oct;90(4):1102-1108.e2
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sternal resection for sarcoma, recurrent breast cancer, and radiation-induced necrosis.
  • METHODS: We performed a 25-year retrospective study of 68 patients who underwent a sternectomy for sarcoma, recurrent breast cancer (BC) or radiation-induced necrosis between 1981 and 2006 in two tertiary referral centres (Erasmus Medical Center/Daniel den Hoed Cancer Center and Netherlands Cancer Center/Antoni van Leeuwenhoek Hospital, Netherlands).
  • RESULTS: Sternal resection was performed in 43 sarcoma patients, 17 recurrent BC and 8 patients with radiation-induced necrosis with additional rib resection in the majority of patients and with clavicle resection in 13% of patients.
  • Radical resection was achieved in 80% and 53% of sarcoma and recurrent BC patients, respectively.
  • Five-year overall survival was 64% and 40% in sarcoma and recurrent BC patients, respectively, with 5-year disease-free survivals of 52% and 15%, respectively.
  • CONCLUSIONS: Sarcomas, recurrent BC, and radiation-induced necrosis can be successfully managed by sternal resection and reconstruction with curative intent.
  • Disease-free survival is poor among recurrent BC patients.
  • [MeSH-major] Breast Neoplasms / surgery. Necrosis / surgery. Neoplasm Recurrence, Local / surgery. Radiation Injuries / complications. Sarcoma / surgery. Sternum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / surgery. Feasibility Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Soft Tissue Neoplasms / surgery. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Radiation induced cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Ann Thorac Surg. 2010 Oct;90(4):1108-9 [20868796.001]
  • (PMID = 20868795.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


25. Abatzoglou S, Turcotte RE, Adoubali A, Isler MH, Roberge D: Local recurrence after initial multidisciplinary management of soft tissue sarcoma: is there a way out? Clin Orthop Relat Res; 2010 Nov;468(11):3012-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence after initial multidisciplinary management of soft tissue sarcoma: is there a way out?
  • BACKGROUND: Multimodality treatment of primary soft tissue sarcoma by expert teams reportedly affords a low incidence of local recurrence.
  • QUESTIONS/PURPOSES: We (1) determined the incidence of local recurrence from soft tissue sarcoma;.
  • (2) compared characteristics of the recurrent tumors with those of the primary ones;.
  • METHODS: From our prospective database, we identified 618 soft tissue sarcomas.
  • RESULTS: Recurrent tumors had a tendency toward becoming deeper seated and higher graded.
  • CONCLUSIONS: Patients with a local recurrence of a soft tissue sarcoma have a poor prognosis.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Orthopedic Procedures. Patient Care Team. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Chi-Square Distribution. Databases as Topic. Female. Humans. Incidence. Kaplan-Meier Estimate. Limb Salvage. Male. Middle Aged. Neoplasm Staging. Quebec. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2003 Jul;15(4):319-26 [12874511.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):218-26 [12560780.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):739-47 [14529779.001]
  • [Cites] Stat Med. 2003 Nov 30;22(22):3515-25 [14601016.001]
  • [Cites] Ann Surg. 1968 Jul;168(1):47-53 [4299767.001]
  • [Cites] Ann Surg. 1975 Nov;182(5):597-602 [1190864.001]
  • [Cites] Ann Surg. 1982 Jul;196(1):87-91 [7092358.001]
  • [Cites] Radiother Oncol. 1990 Jul;18(3):221-33 [2217870.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1229-33 [2045297.001]
  • [Cites] Acta Orthop Scand. 1995 Apr;66(2):147-52 [7740945.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Ann Surg Oncol. 1996 May;3(3):255-60 [8726180.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] Radiother Oncol. 1996 Dec;41(3):209-14 [9027935.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):553-7 [9250737.001]
  • [Cites] Cancer J Sci Am. 1999 Jan-Feb;5(1):26-33 [10188058.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):10-7 [15827772.001]
  • [Cites] Ann Surg Oncol. 2005 Mar;12(3):228-36 [15827815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1124-9 [17208389.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1583-90 [17260106.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1528-9 [17295083.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):81-6 [10694643.001]
  • [Cites] Acta Orthop Scand. 2000 Oct;71(5):488-95 [11186407.001]
  • [Cites] Acta Orthop Scand. 2001 Feb;72(1):72-7 [11327418.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):278-89 [11352300.001]
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):411-5 [12902897.001]
  • (PMID = 20700676.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2947683
  •  go-up   go-down


26. Mocellin S, Rossi CR, Brandes A, Nitti D: Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev; 2006 Feb;32(1):9-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.
  • The therapeutic approach to soft tissue sarcomas (STS) has evolved over the past two decades based on the results from randomized controlled trials, which are guiding physicians in the treatment decision-making process.
  • Despite significant improvements in the control of local disease, a significant number of patients ultimately die of recurrent/metastatic disease following radical surgery due to a lack of effective adjuvant treatments.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Sarcoma / metabolism. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant. Enzyme Inhibitors / therapeutic use. Genetic Therapy. Growth Substances / metabolism. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338075.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cancer Vaccines; 0 / Enzyme Inhibitors; 0 / Growth Substances; 0 / Matrix Metalloproteinase Inhibitors
  • [Number-of-references] 234
  •  go-up   go-down


27. Suppiah R, Wood L, Elson P, Budd GT: Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs; 2006 Nov;24(6):509-14
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
  • METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial.
  • HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Survival Analysis. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791410.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


28. Brady MS, Brown K, Patel A, Fisher C, Marx W: Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res; 2009 Apr;19(2):106-11
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
  • Isolated limb infusion (ILI) is a minimally invasive technique of delivering regional chemotherapy in patients with advanced melanoma or soft-tissue sarcoma of the limb.
  • Eligible patients had recurrent melanoma or unresectable soft-tissue sarcoma of the limb.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Chemotherapy, Cancer, Regional Perfusion. Extremities. Melanoma / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anesthesia, General. Brachial Artery. Catheterization, Peripheral. Dactinomycin / administration & dosage. Female. Humans. Infusions, Intra-Arterial. Male. Melphalan / administration & dosage. Middle Aged. Popliteal Artery. Radiography, Interventional. Remission Induction


29. Lasithiotakis K, Economou G, Gogas H, Ioannou C, Perisynakis K, Filis D, Kastana O, Bafaloukos D, Decatris M, Catodritis N, Frangia K, Papadakis G, Magarakis M, Tsoutsos D, Chrysos E, Chalkiadakis G, Zoras O: Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. Oncol Rep; 2010 Apr;23(4):1077-83
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
  • Herein, we present the experience of the Hellenic collaborating centers with TM-HILP for inoperable in-transit melanoma and soft tissue sarcoma (STS) of the extremities to examine safety and feasibility of collaborating as a multi-institutional group for future research studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced / methods. Melanoma / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Greece. Humans. Leg. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Reproducibility of Results. Retrospective Studies. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204294.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


30. Puhaindran ME, Steensma MR, Athanasian EA: Partial hand preservation for large soft tissue sarcomas of the hand. J Hand Surg Am; 2010 Feb;35(2):291-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial hand preservation for large soft tissue sarcomas of the hand.
  • In patients with large soft tissue sarcomas of the hand, partial hand preservation is extremely challenging for surgeons attempting a complete resection of the tumor with negative resection margins.
  • We conducted this review to examine the oncologic outcome, including local recurrence rate and patient overall survival, and functional outcome after resections for large soft tissue sarcomas with partial hand preservation.
  • METHODS: We performed a retrospective review of all patients with soft tissue sarcomas of the hand treated at our institution from 1995 to 2007.
  • Two patients had myxofibrosarcoma, 2 patients had synovial sarcoma, 2 patients had malignant fibrous histiocytoma, 1 patient had a malignant peripheral nerve sheath tumor, and 1 patient had a liposarcoma.
  • RESULTS: Of the 8 patients, 1 died of distant metastatic disease, 1 developed local tumor recurrence and is alive with locally recurrent disease, and the other 6 patients are completely disease-free.
  • CONCLUSIONS: Partial hand preservation is possible in selected patients with large soft tissue sarcomas of the hand, obtaining low local recurrence rates, good overall survival, and good functional outcome.
  • [MeSH-major] Hand / surgery. Limb Salvage / methods. Neoplasm Recurrence, Local / pathology. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / methods. Arm. Artificial Limbs. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prosthesis Fitting. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20141899.001).
  • [ISSN] 1531-6564
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Di Filippo F, Giacomini P, Rossi CR, Santinami M, Garinei R, Anzà M, Deraco M, Botti C, Perri P, Cavaliere F, Di Angelo P, Sofra C, Sperduti I, Pasqualoni R, Di Filippo S, Corrias F, Armenti A, Ferraresi V: Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo; 2009 Mar-Apr;23(2):363-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
  • BACKGROUND: Tumor necrosis factor-alpha (TNFalpha)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFalpha dosages.
  • PATIENTS AND METHODS: HILP with TNFalpha (at a dosage of either <or=1 mg or >1 mg) and Dx was administered to 75 patients with limb-threatening STS: 37 males and 38 females; median age 50 years; tumor in the lower and upper limbs in 58 and 17 patients, respectively; primary and recurrent tumors in 45 and 30 patients, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Doxorubicin / administration & dosage. Hyperthermia, Induced. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Cancer, Regional Perfusion / methods. Disease-Free Survival. Extremities / pathology. Female. Humans. Male. Middle Aged. Perfusion. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414428.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin
  •  go-up   go-down


32. Weng WH, Ahlén J, Aström K, Lui WO, Larsson C: Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res; 2005 Sep 1;11(17):6198-204
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas.
  • It has recently been reported to be involved in dissemination of pediatric soft tissue sarcoma (STS).
  • Similarly, ezrin expression was significantly associated with development of distant metastasis during follow-up (P = 0.031), also excluding locally recurrent disease (P = 0.049).
  • [MeSH-major] Phosphoproteins / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Membrane / metabolism. Chromosomes, Human, Pair 9 / genetics. Cytoplasm / metabolism. Cytoskeletal Proteins. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Nucleic Acid Hybridization. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144921.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Ki-67 Antigen; 0 / Phosphoproteins; 0 / ezrin
  •  go-up   go-down


33. Pawlik TM, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, Ballo MT, Catton CN, Jones JJ, O'Sullivan B, Pollock RE, Swallow CJ: Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol; 2006 Apr;13(4):508-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma.
  • BACKGROUND: The reported data on surgery plus radiotherapy for retroperitoneal soft tissue sarcomas (RPS) have been mostly from retrospective studies.
  • Fifty-four patients (75%) had primary RPS, whereas 18 (25%) had recurrent disease.
  • [MeSH-major] Neoplasm Recurrence, Local. Preoperative Care. Retroperitoneal Space. Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2006 Apr;13(4):442-3 [16511670.001]
  • (PMID = 16491338.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Leow AM, Halim AS, Wan Z: Reconstructive treatment following resection of high-grade soft-tissue sarcomas of the lower limb. J Orthop Surg (Hong Kong); 2005 Apr;13(1):58-63
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstructive treatment following resection of high-grade soft-tissue sarcomas of the lower limb.
  • PURPOSE: To review the role of free tissue transfer in reconstructive surgery following resection of high-grade soft-tissue sarcomas of the lower limb.
  • METHODS: Medical records of all consecutive patients with high-grade soft-tissue sarcomas of the lower limbs between August 1997 and September 2003 were reviewed.
  • RESULTS: Of 8 patients (6 women and 2 men) aged between 19 and 65 years, 4 had malignant fibrous histiocytoma, one had malignant peripheral nerve sheath tumour, one had synovial sarcoma, one had recurrent liposarcoma, and one had epitheloid sarcoma.
  • The soft-tissue defects following tumour extirpation ranged from 153 cm(2) to 896 cm(2).
  • CONCLUSION: Tissue transfer allows early adjuvant therapy facilitating the multimodal approach for the high-grade soft-tissue sarcomas of the lower extremity.
  • [MeSH-major] Lower Extremity. Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Female. Humans. Limb Salvage. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15872402.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Wang WL, Mayordomo E, Zhang W, Hernandez VS, Tuvin D, Garcia L, Lev DC, Lazar AJ, López-Terrada D: Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol; 2009 Sep;22(9):1201-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts).
  • Unlike melanoma, clear cell sarcoma harbors either a t(12;22)(q13;q12) recurrent translocation, resulting in an EWSR1/ATF1 chimeric gene, or less commonly a t(2;22)(q34;q12) translocation fusing EWSR1 and CREB1.
  • Fluorescence in situ hybridization (FISH) analysis using the LSI EWSR1 break-apart probe and a reverse transcription polymerase chain reaction (RT-PCR) assay optimized for formalin-fixed paraffin-embedded tissue to detect all four reported EWSR1/ATF1 clear cell sarcoma chimeric types and the EWSR1/CREB1 variant was performed.
  • Consequently, both techniques are equally effective in assessing for an EWSR1 rearrangement and are useful ancillary diagnostic tests for clear cell sarcoma.
  • In addition, EWSR1-CREB1 was identified in a clear cell sarcoma of soft tissue providing further evidence that this chimeric variant is not exclusive to gastrointestinal clear cell sarcomas and should be included in RT-PCR assays of soft tissue clear cell sarcomas.
  • [MeSH-major] CREB-Binding Protein / genetics. Calmodulin-Binding Proteins / genetics. Oncogene Proteins, Fusion / genetics. RNA-Binding Proteins / genetics. Sarcoma, Clear Cell / genetics. Soft Tissue Neoplasms / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561568.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CREBBP protein, human; 0 / Calmodulin-Binding Proteins; 0 / EWS-ATF1 fusion protein, human; 0 / EWSR1 protein, human; 0 / EWSR1-CREB1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA-Binding Proteins; 0 / Transcription Factors; EC 2.3.1.48 / CREB-Binding Protein
  •  go-up   go-down


36. van Ginkel RJ, Thijssens KM, Pras E, van der Graaf WT, Suurmeijer AJ, Hoekstra HJ: Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol; 2007 Apr;14(4):1499-506
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
  • BACKGROUND: The aim of this study was to investigate the long-term limb salvage rate and overall survival after isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma (STS).
  • The first was within a year after perfusion, mainly as a result of massive necrosis of the tumor and overlying skin, resulting in soft tissue deficit or recurrent disease (n = 17).
  • [MeSH-major] Amputation. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Risk Factors. Survival Rate. Tumor Necrosis Factor-alpha / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):745-50 [11020571.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):616-21 [2743257.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):792-7 [11087648.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):355-63 [11986187.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1483-90 [14508836.001]
  • [Cites] Radiology. 1971 Nov;101(2):429-33 [5114783.001]
  • [Cites] Br J Radiol. 1974 Feb;47(554):157-8 [4817460.001]
  • [Cites] Radiat Res. 1975 Jul;63(1):157-64 [1144676.001]
  • [Cites] Ann Surg. 1977 May;185(5):555-64 [266397.001]
  • [Cites] Ann Surg. 1980;192(4):431-8 [6932827.001]
  • [Cites] Cancer. 1981 May 1;47(9):2269-74 [7226121.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Am J Surg. 1988 May;155(5):667-71 [3369621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):52-60 [1727926.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2140-6 [8156518.001]
  • [Cites] Arch Surg. 1995 Jan;130(1):43-7 [7802575.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):382-8 [7850539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1289-300 [7635768.001]
  • [Cites] Arch Surg. 1996 Jun;131(6):672-4 [8645079.001]
  • [Cites] Crit Care Med. 1996 May;24(5):765-70 [8706451.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):528-31 [8903498.001]
  • [Cites] Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 [8968230.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1129-37 [9070490.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Clin Orthop Relat Res. 1998 Jul;(352):168-78 [9678045.001]
  • [Cites] Cancer Treat Rev. 1998 Dec;24(6):373-91 [10189405.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):669-78 [11078614.001]
  • (PMID = 17253101.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC1914273
  •  go-up   go-down


37. Llácer C, Delannes M, Minsat M, Stoeckle E, Votron L, Martel P, Bonnevialle P, Nguyen Bui B, Chevreau C, Kantor G, Daly-Schveitzer N, Thomas L: Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure. Radiother Oncol; 2006 Jan;78(1):10-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure.
  • BACKGROUND AND PURPOSE: To evaluate intraoperative brachytherapy in the management of soft tissue sarcomas involving neurovascular structures, its impact on local control and complications.
  • Brachytherapy was part of the initial treatment (79 cases) or performed in recurrent disease (19 cases).
  • CONCLUSIONS: Intraoperative brachytherapy is efficient with excellent local control rates in soft tissue sarcomas presenting with neurovascular involvement and offers an acceptable conservative option.
  • [MeSH-major] Brachytherapy. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Intraoperative Period. Iridium Radioisotopes / therapeutic use. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376446.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


38. Evans SM, Fraker D, Hahn SM, Gleason K, Jenkins WT, Jenkins K, Hwang WT, Zhang P, Mick R, Koch CJ: EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys; 2006 Mar 1;64(3):922-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EF5 binding and clinical outcome in human soft tissue sarcomas.
  • PURPOSE: To study the 2-nitroimidazole agent EF5 as a surrogate for measuring hypoxia in a series of patients with soft tissue sarcomas, and to determine whether hypoxia measured with this technique was associated with patient outcome.
  • METHODS AND MATERIALS: Patients with soft tissue sarcomas of the head and neck, extremity, trunk, or retroperitoneum for whom surgical excision was the initial treatment of choice, were given 21 mg/kg EF5 24-48 hours before surgery.
  • RESULTS: Two patients with recurrent and 14 patients with de novo sarcomas were studied.
  • [MeSH-major] Cell Hypoxia / physiology. Etanidazole / analogs & derivatives. Hydrocarbons, Fluorinated / metabolism. Indicators and Reagents / metabolism. Neoplasm Recurrence, Local / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458778.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00040; United States / NCI NIH HHS / CA / R01 CA 75285
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; 0 / Hydrocarbons, Fluorinated; 0 / Indicators and Reagents; 30DKA3Q1HL / Etanidazole
  •  go-up   go-down


39. Wong CH, Tan BK, Koong HN, Lim CH, Chia SJ, Song C: Use of the omentum flap as additional soft-tissue cover for abdominal wall defects reconstructed with Gore-Tex. Plast Reconstr Surg; 2005 Nov;116(6):1715-20
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the omentum flap as additional soft-tissue cover for abdominal wall defects reconstructed with Gore-Tex.
  • These defects resulted from tumor resection and recurrent incisional hernia.
  • CONCLUSION: The omentum flap served as an additional soft-tissue cover over the Gore-Tex repair to prevent exposure in the event of infection or flap breakdown.
  • [MeSH-minor] Adult. Female. Hernia, Abdominal / surgery. Humans. Male. Muscle Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Omentum. Prosthesis-Related Infections / surgery. Recurrence. Sarcoma / surgery. Surgical Flaps. Wound Healing

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2006 Jan;117(1):312-3 [16404285.001]
  • (PMID = 16267436.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


40. Popov P, Barner-Rasmussen I, Tukiainen E: Microvascular flaps and collateral ligament reconstructions for soft tissue sarcomas at the knee joint. Ann Plast Surg; 2010 Jan;64(1):24-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvascular flaps and collateral ligament reconstructions for soft tissue sarcomas at the knee joint.
  • We report the suitability of free flap reconstruction in defects around the knee joint caused by soft tissue sarcoma (STS) excisions.
  • Of these, 2 patients with solitary soft tissue metastasis were operated, and they are disease free.
  • One patient with medial collateral reconstruction had recurrent patellar displacement and needed further operations; another with lateral collateral ligament and posterior capsular excision, that was not reconstructed, had lateral instability of the knee and needed orthosis.Free flap for STS of the knee is a reliable method.
  • [MeSH-major] Ligaments / surgery. Microsurgery / methods. Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Knee Joint. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023452.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Garner HW, Kransdorf MJ, Bancroft LW, Peterson JJ, Berquist TH, Murphey MD: Benign and malignant soft-tissue tumors: posttreatment MR imaging. Radiographics; 2009 Jan-Feb;29(1):119-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant soft-tissue tumors: posttreatment MR imaging.
  • Soft-tissue sarcoma requires aggressive treatment, often with a combination of radiation therapy, chemotherapy, and surgical resection.
  • The challenge of distinguishing posttreatment change from recurrent tumor may be minimized by using an organized, systematic approach to imaging, with emphasis on the patient's clinical and surgical history and a review of pretreatment images.
  • Common changes that result from radiation therapy include soft-tissue trabeculation, increased fatty marrow, and focal marrow abnormalities.
  • Recurrent tumor is characterized by the presence of a discrete nodule or mass with signal characteristics that typically mirror those of the original tumor.
  • [MeSH-major] Image Enhancement / methods. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Postoperative Care / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19168840.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Germain MA, Bonvalot S, Rimareix F, Missana CM: [Locally advanced soft-tissue sarcomas. An innovating triad to avoid amputation: isolated limb perfusion, TNFalpha, and free microsurgical flap]. Bull Acad Natl Med; 2010 Jan;194(1):51-65; discussion 65-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced soft-tissue sarcomas. An innovating triad to avoid amputation: isolated limb perfusion, TNFalpha, and free microsurgical flap].
  • We retrospectively studied the benefits of isolated limb perfusion combined with TNFalpha administration and free flap reconstruction in locally advanced soft-tissue sarcomas of the limbs.
  • Between 2000 and 2008, we treated 37 patients (22 women and 15 men) with locally advanced soft tissue sarcomas.
  • They were multifocal in 8 cases and recurrent in 15 cases.
  • Sarcoma excision was combined with a complementary procedure in 10 patients (vascular graft or nerve anastomosis).
  • Three major improvements were made in recent years, namely isolated limb perfusion, TNFalpha administration, and free flap reconstruction two months after resection of residual sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Male. Middle Aged. Muscle, Skeletal / transplantation. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Radiation-Induced / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / surgery. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures. Reoperation. Retrospective Studies. Skin Transplantation. Surgical Flaps. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669559.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


48. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol; 2005 Oct 1;23(28):7135-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
  • PURPOSE: To evaluate the antitumor activity and tolerability of bevacizumab and doxorubicin in patients with metastatic soft-tissue sarcoma (STS).
  • One patient with extensive lung disease died of recurrent bilateral pneumothoraces, possibly treatment-related.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Doxorubicin / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192597.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01 CA47179
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 80168379AG / Doxorubicin
  •  go-up   go-down


49. Thway K, Fisher C, Debiec-Rychter M, Calonje E: Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. Hum Pathol; 2009 Nov;40(11):1586-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma.
  • Low-grade fibromyxoid sarcoma is a soft tissue sarcoma with recurrent and low metastatic potential, which has characteristic FUS-CREB3L2 or FUS-CREB3L1 fusions.
  • Low-grade fibromyxoid sarcoma and perineurioma can appear morphologically similar, particularly in small biopsy specimens, and distinction between the 2 entities is important for appropriate treatment.
  • Low-grade fibromyxoid sarcoma is negative for most immunohistochemical markers, whereas perineuriomas stain variably for epithelial membrane antigen, CD34 and claudin-1, a tight-junction associated protein.
  • We studied 15 cases of genetically proven low-grade fibromyxoid sarcoma that at least focally resembled perineurioma, with antibodies to claudin-1 and epithelial membrane antigen.
  • This has implications toward the accurate diagnosis of both tumors, and, as positivity for claudin-1 in low-grade fibromyxoid sarcoma is not previously documented, suggests that there might be underdiagnosis of low-grade fibromyxoid sarcoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Fibrosarcoma / pathology. Membrane Proteins / biosynthesis. Nerve Sheath Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Claudin-1. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mucin-1 / biosynthesis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540561.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins; 0 / Mucin-1
  •  go-up   go-down


50. Petera J, Soumarová R, Růzicková J, Neumanová R, Dusek L, Sirák I, Macingová Z, Paluska P, Kasaová L, Hodek M, Vosmik M: Perioperative hyperfractionated high-dose rate brachytherapy for the treatment of soft tissue sarcomas: multicentric experience. Ann Surg Oncol; 2010 Jan;17(1):206-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative hyperfractionated high-dose rate brachytherapy for the treatment of soft tissue sarcomas: multicentric experience.
  • BACKGROUND: Low-dose rate brachytherapy is a well-established adjuvant treatment for soft tissue sarcomas (STS).
  • METHODS: Forty-five patients with primary (17 cases) or recurrent (28 cases) STS were treated with resection and HDR BT between 1998 and 2007.
  • [MeSH-major] Brachytherapy. Neoplasm Recurrence, Local / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Perioperative Care. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711130.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Fréneaux P: [Soft tissue non lymphoid malignant round cell tumors in childhood and adolescence: morphological, immunophenotypic, and molecular features of diagnosis]. Ann Pathol; 2006 Apr;26(2):97-109

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue non lymphoid malignant round cell tumors in childhood and adolescence: morphological, immunophenotypic, and molecular features of diagnosis].
  • Soft tissue non lymphoid malignant round cell tumors observed in children and adolescents are rare and are very different from adult tumors.
  • They are often undifferentiated and distinctive key morphologic features are often lacking, but, on the other hand, specific recurrent genetic alterations, mostly translocations, are distinctive.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Chromosome Mapping. Diagnosis, Differential. Humans. Immunophenotyping. Lung Neoplasms / pathology. Neuroblastoma / pathology. Neuroectodermal Tumors, Primitive / pathology. Paraganglioma / pathology. Rhabdoid Tumor / pathology. Rhabdomyosarcoma / pathology. Sarcoma, Ewing / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791121.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


52. Ng VY, Thomas K, Crist M, Wakely PE Jr, Mayerson J: Fine needle aspiration for clinical triage of extremity soft tissue masses. Clin Orthop Relat Res; 2010 Apr;468(4):1120-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration for clinical triage of extremity soft tissue masses.
  • BACKGROUND: Fine needle aspiration cytology (FNAC) is a rapid and low-morbid alternative to open biopsy or needle core biopsy for soft tissue masses.
  • Numerous reports describe its use with metastatic or recurrent lesions, but FNAC is less accepted for primary lesions.
  • METHODS: We retrospectively examined the diagnostic accuracy and clinical effectiveness of office-based FNAC performed by a trained pathologist on 213 females and 219 males (mean age, 51.8 years) who presented with a palpable soft tissue mass to one musculoskeletal oncology clinic between 2002 and 2008.
  • Final tissue confirmation by open biopsy or resection was available for 52.2% of benign FNAC and 78.3% of malignant FNAC.
  • [MeSH-major] Biopsy, Fine-Needle. Extremities / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Triage / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):337-43 [10833988.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):59-68 [11190808.001]
  • [Cites] Diagn Cytopathol. 2001 May;24(5):307-16 [11335959.001]
  • [Cites] Acta Orthop Scand. 2001 Apr;72(2):150-9 [11372946.001]
  • [Cites] Cancer Control. 2001 May-Jun;8(3):232-8 [11378649.001]
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):232-42 [11933269.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):83-91 [11954025.001]
  • [Cites] Diagn Cytopathol. 2002 Jul;27(1):1-4 [12112806.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):354-61 [12451566.001]
  • [Cites] Cytopathology. 2003 Aug;14(4):173-82 [12873307.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):24-37 [14676638.001]
  • [Cites] Cytopathology. 2004 Feb;15(1):32-7 [14748789.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):759-64 [15214827.001]
  • [Cites] Acta Orthop Scand. 1985 Oct;56(5):407-12 [4072661.001]
  • [Cites] Arch Pathol Lab Med. 1986 May;110(5):420-4 [3754426.001]
  • [Cites] Acta Cytol. 1986 Nov-Dec;30(6):671-8 [3466503.001]
  • [Cites] J Surg Oncol. 1988 Mar;37(3):168-70 [3352270.001]
  • [Cites] Hum Pathol. 1990 Jun;21(6):669-77 [2190911.001]
  • [Cites] Surgery. 1992 Sep;112(3):536-43 [1519170.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):381-4 [8191828.001]
  • [Cites] Cytopathology. 1995 Aug;6(4):236-47 [8520003.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):639-43 [8642018.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):644-9 [8642019.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Am J Surg. 1997 Dec;174(6):694-6; discussion 697-8 [9409599.001]
  • [Cites] Cytopathology. 1998 Oct;9(5):320-8 [9800130.001]
  • [Cites] Virchows Arch. 1999 Mar;434(3):187-91 [10190296.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):632-40 [10230353.001]
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):388-93 [15716235.001]
  • [Cites] Ann Diagn Pathol. 2005 Aug;9(4):197-201 [16084452.001]
  • [Cites] Cancer. 2005 Aug 25;105(4):229-39 [15918176.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):815-9 [16557276.001]
  • [Cites] Clin Orthop Relat Res. 2006 Sep;450:95-100 [16906075.001]
  • [Cites] Diagn Cytopathol. 2007 Dec;35(12):768-73 [18008345.001]
  • [Cites] Cancer. 2007 Dec 25;111(6):491-8 [17941014.001]
  • [Cites] Cancer. 2000 Oct 25;90(5):292-8 [11038426.001]
  • (PMID = 19763717.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2835602
  •  go-up   go-down


53. Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS: Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer; 2005 Apr;44(4):338-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
  • BACKGROUND: The prognosis for children with recurrent/refractory sarcomas is poor.
  • We determined the overall response rate (ORR) and overall survival (OS) of children with recurrent/refractory sarcomas who were given ifosfamide, carboplatin, and etoposide (ICE) in three Children's Cancer Group (CCG) phase I/II trials.
  • PROCEDURE: Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs. 5 microg/kg/day, CCG-0894, 71 patients), PIXY321 (500-1,000 microg/m2/day, CCG-0924, 14 patients), or rhG-CSF (5 microg/kg/day) and IL-6 (2.5-5 microg/kg/day, CCG-0931, 12 patients).
  • Tumor types were osteosarcoma (OTS) (n = 34), rhabdomyosarcoma (n = 27), Ewing sarcoma (EWS) (n = 21), soft tissue sarcoma-not otherwise specified (n = 5), undifferentiated sarcoma (n = 6), fibrosarcoma (n = 2), peripheral primitive neuroectodermal tumor (n = 1), and extraosseous Ewing (n = 1).
  • CONCLUSIONS: The ORR to ICE reinduction chemotherapy in children with recurrent/refractory sarcoma was 51%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child. Child, Preschool. Colony-Stimulating Factors / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Multivariate Analysis. Proportional Hazards Models. Recurrence. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / mortality. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503297.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colony-Stimulating Factors; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


54. Matthews A, Tang M, Cooper K: Cytogenetic aberrations in soft tissue tumors harvested from fresh tissue submitted for surgical pathology: a single institutional experience. Int J Surg Pathol; 2010 Aug;18(4):260-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic aberrations in soft tissue tumors harvested from fresh tissue submitted for surgical pathology: a single institutional experience.
  • AIMS: Recurrent cytogenetic abnormalities have been reported in many types of soft tissue neoplasms, and the detection of these aberrations imparts diagnostic utility.
  • The aim of this study is to demonstrate that classical karyotyping may be performed with minimal effort as an adjunct to surgical pathology on fresh tissue submitted for histopathological examination.
  • To the authors' knowledge, there are no recently published reviews in the literature in English of cytogenetic abnormalities in soft tissue tumors from a single institution.
  • METHODS: Conventional metaphase cytogenetics was performed in the authors' cytogenetics laboratory on fresh tissue from mesenchymal tumors from their surgical pathology laboratory over a period of 4 years.
  • Cytogenetics reports, clinical history, and histopathology were reviewed for 48 soft tissue tumors.
  • Recurrent cytogenetic abnormalities were identified using the Mitelman Database of Chromosome Aberrations in Cancer and a review of the literature.
  • RESULTS: The authors reviewed 48 cases of benign and malignant soft tissue tumors, which included 28 distinct morphologies.
  • [MeSH-major] Chromosome Aberrations. Pathology, Surgical / methods. Sarcoma / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Karyotyping. Male. Middle Aged. Neoplasm Recurrence, Local. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776087.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Bilici A, Ustaalioglu BB, Seker M, Kayahan S: Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature. Clin Orthop Relat Res; 2010 Sep;468(9):2541-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature.
  • Spread to soft tissue, however, is rare with only four cases with seminoma reported.
  • However, one case with metastasis of testicular immature teratoma to soft tissue was documented previously.
  • CASE DESCRIPTION: We report the case of a 38-year-old man with recurrent immature teratoma of the testis who presented with a painless soft tissue mass in the left thigh previously treated with standard chemotherapy.
  • After removal of the soft tissue mass, his serum alpha-fetoprotein level had returned to the normal range.
  • LITERATURE REVIEW: To our knowledge, this is the second case of immature teratoma of the testis metastasized to soft tissue.
  • PURPOSES AND CLINICAL RELEVANCE: We suggest that for a man with testicular cancer who has a soft tissue mass, metastasis of soft tissue from testicular cancer and other solid malignancies should be considered in the differential diagnosis of a soft tissue mass together with primary soft tissue sarcoma.
  • [MeSH-major] Soft Tissue Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Brain Neoplasms / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Cranial Irradiation. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Magnetic Resonance Imaging. Male. Orchiectomy. Thigh. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Br J Radiol. 2008 Jul;81(967):e188-90 [18559897.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1644; author reply 1644 [12438072.001]
  • [Cites] Jpn J Clin Oncol. 2004 Apr;34(4):210-4 [15121758.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Urology. 1985 Apr;25(4):398-400 [2984822.001]
  • [Cites] AJR Am J Roentgenol. 1985 Dec;145(6):1165-71 [2998169.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):805-8 [2820673.001]
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Acta Neurol Belg. 2005 Sep;105(3):178-9 [16255156.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Singapore Med J. 2007 Mar;48(3):e77-80 [17342276.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):672-84 [18270356.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • (PMID = 19937408.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC2919860
  •  go-up   go-down


56. Petera J, Neumanová R, Odrazka K, Ondrak M, Prochazka E: Perioperative hyperfractionated high-dose rate brachytherapy combined with external beam radiotherapy in the treatment of soft tissue sarcomas. Tumori; 2005 Jul-Aug;91(4):331-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative hyperfractionated high-dose rate brachytherapy combined with external beam radiotherapy in the treatment of soft tissue sarcomas.
  • AIMS AND BACKGROUND: Low-dose rate brachytherapy alone or in combination with external beam radiotherapy represents a well-established adjuvant treatment in soft tissue sarcomas following surgical resection.
  • The purpose of our study was an evaluation of the viability of perioperative hyperfractionated high-dose rate brachytherapy in combination with external beam radiotherapy for primary and recurrent soft tissue sarcomas.
  • PATIENTS AND METHODS: From February 1998 through June 2002, 10 adult patients with soft tissue sarcomas were treated by interstitial perioperative high-dose rate brachytherapy and external beam radiotherapy.
  • CONCLUSIONS: Our study on a small number of patients suggests that perioperative hyperfractionated high-dose rate brachytherapy with doses 8 x 3 Gy in combination with external beam radiotherapy 40-50 Gy is a promising method to achieve high biological doses in the postoperative radiotherapy of soft tissue sarcomas without severe late morbidity and warrants further research.
  • [MeSH-major] Brachytherapy / methods. Neoplasm Recurrence, Local / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Female. Humans. Iridium Radioisotopes / therapeutic use. Male. Middle Aged. Perioperative Care / methods. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277099.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


57. Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, Ravi V, Lazar AJ, Lev D: Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol; 2009 Sep;16(9):2502-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of locally recurrent and metastatic angiosarcoma.
  • BACKGROUND: Angiosarcoma (AS) is a rare soft tissue sarcoma with an enhanced propensity for local and systemic failure.
  • The outcome of locally recurrent and metastatic AS treated at a single institution was evaluated.
  • RESULTS: Forty-four patients were treated for locally recurrent AS; the majority (59%) were <or=5 cm; the most common sites were skin (48%) and breast (32%).
  • Multivariable analysis identified size >5 cm as the only independent adverse prognosticator of recurrent AS-specific survival [hazard ratio (HR): 3.26, P = 0.04].
  • CONCLUSION: Locally recurrent AS is often treatable; complete resection can potentially prolong survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19551444.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Bonvalot S, Rimareix F, Causeret S, Le Péchoux C, Boulet B, Terrier P, Le Cesne A, Muret J: Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol; 2009 Dec;16(12):3350-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
  • The objective of the present study was to confirm these data on a larger sample size of locally advanced or recurrent extremity soft tissue sarcomas with low-dose TNF-alpha.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Fibromatosis, Aggressive / therapy. Hyperthermia, Induced. Melphalan / administration & dosage. Sarcoma / therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19830495.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


59. Srivastava A, Rosenberg AE, Selig M, Rubin BP, Nielsen GP: Keratin-positive Ewing's sarcoma: an ultrastructural study of 12 cases. Int J Surg Pathol; 2005 Jan;13(1):43-50
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratin-positive Ewing's sarcoma: an ultrastructural study of 12 cases.
  • Ewing's sarcoma/primitive neuroectodermal tumor (EWS/PNET) is an aggressive neoplasm of bone and soft tissue.
  • The cohort includes 5 patients with a type-1 translocation, which has been associated with a better prognosis in some studies; 4 of these patients have died of their disease, and 1 is alive with recurrent disease.
  • [MeSH-major] Bone Neoplasms / ultrastructure. Keratins. Neuroectodermal Tumors, Primitive, Peripheral / ultrastructure. Sarcoma, Ewing / ultrastructure. Soft Tissue Neoplasms / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Fatal Outcome. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1. RNA, Neoplasm / analysis. RNA-Binding Protein EWS. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735854.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA, Neoplasm; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors; 68238-35-7 / Keratins
  •  go-up   go-down


60. Aulmann S, Longerich T, Schirmacher P, Mechtersheimer G, Penzel R: Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas. Histopathology; 2007 Jun;50(7):881-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas.
  • AIMS: Alveolar soft part sarcoma (ASPS) is a rare soft tissue tumour with unique morphology and a recurrent, non-reciprocal translocation der(17)t(X;17)(p11.2;q25) leading to the fusion of ASPSCR1 (also known as ASPL) to the transcription factor TFE3.
  • The aim of this study was to analyse the chromosomal breakpoints in paraffin-embedded tissue.
  • [MeSH-major] Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Neoplasm Proteins / genetics. Oncogene Fusion. Oncogene Proteins, Fusion / genetics. Sarcoma, Alveolar Soft Part / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Child, Preschool. Chromosomes, Human, Pair 17. Chromosomes, Human, X. DNA, Neoplasm / analysis. Female. Humans. In Situ Hybridization, Fluorescence. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ASPSCR1 protein, human; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / TFE3 protein, human
  •  go-up   go-down


61. Waters B, Panicek DM, Lefkowitz RA, Antonescu CR, Healey JH, Athanasian EA, Brennan MF: Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol; 2007 Feb;188(2):W193-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease.
  • This study was undertaken to determine and show patterns of recurrent low-grade myxofibrosarcoma at CT and MRI.
  • CONCLUSION: Unlike in most other histologic types of low-grade soft-tissue sarcoma, recurrent low-grade myxofibrosarcoma often is infiltrative; shows a tapering, tail-like margin and superficial spreading configuration; and metastasizes to various distant sites, including lungs, pleura, bone, adrenal gland, soft tissue, and mesentery.
  • Knowledge of these unusual characteristics is important in assessing the presence and extent of recurrent low-grade myxofibrosarcoma before surgical reexcision.
  • [MeSH-major] Fibrosarcoma / diagnosis. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Soft Tissue Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242227.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. van Akkooi AC, Verhoef C, van Geel AN, Kliffen M, Eggermont AM, de Wilt JH: Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol; 2006 Nov;32(9):996-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy for clear cell sarcoma.
  • Clear cell sarcoma (CCS), also known as clear cell sarcoma of tendons and aponeuroses or malignant melanoma of soft tissue, is a rare malignant tumor and is histogenitically related to melanoma.
  • Only the patients with tumor positive SNs developed recurrent disease during an average follow-up of 33 months.
  • None of the negative SN patients developed recurrent disease and all were alive after an average follow-up of 39 months.
  • SN status seems to predict additional nodal involvement and recurrent disease as well as survival.
  • [MeSH-major] Lymphatic Metastasis / radionuclide imaging. Sarcoma, Clear Cell / pathology. Sentinel Lymph Node Biopsy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lymph Node Excision. Male. Middle Aged. Radiopharmaceuticals. Technetium Tc 99m Aggregated Albumin. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672185.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


63. Rossi CR, Mocellin S, Pilati P, Foletto M, Campana L, Quintieri L, De Salvo GL, Lise M: Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol; 2005 May;12(5):398-405
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
  • BACKGROUND: Tumor necrosis factor (TNF)-alpha-based hyperthermic isolated limb perfusion (HILP) is one of the most active available approaches for locally advanced soft tissue sarcomas (STS) of the limbs.
  • METHODS: HILP with low-dose TNF-alpha (1 mg) and DXR (8.5 mg/L of limb volume) was given to 21 patients with limb-threatening STS: 14 had primary and 7 had recurrent STS, most of which were high grade (grade 1, n = 3; grade 2, n = 6; grade 3, n = 12).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Doxorubicin / administration & dosage. Hyperthermia, Induced. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915374.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin
  •  go-up   go-down


64. Raney RB: Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol; 2005 Apr;27(4):207-11
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions.
  • Synovial sarcoma represents 5% to 10% of all soft tissue sarcomas, with an estimated total of 800 new cases annually in the United States.
  • Anderson Cancer Center's Division of Pediatrics, St. Jude Children's Research Hospital, the German Cooperative Group, and Istituto Nazionale dei Tumori, Milan, found that, as in older people, tumor size larger than 5 cm, residual local tumor or metastases at diagnosis, and progressive or recurrent disease all portended a poor outcome.
  • There are currently no randomized studies of therapy for patients with synovial sarcoma, but such are needed to provide answers to the following questions: Is adjuvant chemotherapy useful in preventing recurrence in patients without visible residual disease after apparently complete surgical removal of localized tumor?
  • [MeSH-major] Sarcoma, Synovial / pathology. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / pathology. Prognosis. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838392.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Dhillon MS, Mootha AK, Kumar V, Saini R, Bharti S: Low-grade fibromyxoid sarcoma of the talus: a case report. J Foot Ankle Surg; 2010 Jul-Aug;49(4):400.e5-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade fibromyxoid sarcoma of the talus: a case report.
  • Low-grade fibromyxoid sarcoma is a rare tumor, which most commonly arises from the deep soft tissues of the lower extremities in young men.
  • Like many soft tissue tumors, low-grade fibromyxoid sarcoma is also characterized by strong immunoreactivity to the human proto-oncogene BCL-2.
  • In this report, we describe the rare case of a low-grade fibromyxoid sarcoma that appeared to develop as a primary malignancy in the neck of the talus of a young man who presented with recurrent ankle pain after a previous surgery for a cystic lesion at the same site.
  • [MeSH-major] Bone Neoplasms / pathology. Sarcoma / pathology. Talus
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20510633.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Mitsuhashi A, Nagai Y, Suzuka K, Yamazawa K, Nojima T, Nikaido T, Ishikura H, Matsui H, Shozu M: Primary synovial sarcoma in fallopian tube: case report and literature review. Int J Gynecol Pathol; 2007 Jan;26(1):34-7
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary synovial sarcoma in fallopian tube: case report and literature review.
  • Synovial sarcoma, a malignant mesenchymal neoplasm, occurs mostly near the joints of the extremities and occasionally outside the joint such as lung.
  • We report a case of soft tissue sarcoma arising in the fallopian tube origin that showed characteristic pathological appearance of biphasic synovial sarcoma.
  • Molecular analysis detected a fusion gene transcript of synovial sarcoma translocation (SYT) gene from chromosome 18 and synovial sarcoma X chromosome breakpoint 1 (SSX1) gene, which is believed to pathognomonic for synovial sarcoma of joint origin.
  • Recurrent abdominal tumor, observed at 12 month after the initial surgery and following chemotherapy using doxorubicin, cisplatin and ifosfamide, partially responded to chemotherapy using paclitaxel and carboplatin and, then, optimal surgery was performed.
  • This is the first report of a synovial sarcoma arising in the fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Adult. Base Sequence. Female. Humans. Oncogene Proteins, Fusion / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197895.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  • [Number-of-references] 12
  •  go-up   go-down


67. Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, Somlo G: Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. Anticancer Res; 2009 Aug;29(8):3281-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
  • BACKGROUND: Patients with locally advanced or metastatic/recurrent soft tissue and Ewing's sarcoma (EWS) have few treatment options.
  • CONCLUSION: Our study demonstrates the feasibility and safety of tandem HDCT in patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term PFS and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Ifosfamide / administration & dosage. Immunoenzyme Techniques. Male. Melphalan / administration & dosage. Mesna / administration & dosage. Neoplasm Staging. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Neuroectodermal Tumors, Primitive, Peripheral / therapy. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Prospective Studies. Protective Agents / administration & dosage. Remission Induction. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Safety. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy. Survival Rate. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661346.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protective Agents; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


68. Elco CP, Mariño-Enríquez A, Abraham JA, Dal Cin P, Hornick JL: Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link. Am J Surg Pathol; 2010 Nov;34(11):1723-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link.
  • Myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor are rare, slow-growing soft tissue tumors of the distal extremities with recurrent potential.
  • Here we report a case of a 42-year-old female with a soft tissue tumor of the ankle showing hybrid morphologic features of myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor, a der(10)t(1;10), and abnormalities of chromosome 3.
  • [MeSH-major] Chromosomes, Human. Fibrosarcoma / genetics. Hemosiderosis / genetics. Lipoma / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adult. Ankle. Biopsy. Chromosome Aberrations. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 3. Female. Humans. Karyotyping. Magnetic Resonance Imaging. Neoadjuvant Therapy. Orthopedic Procedures. Radiotherapy, Adjuvant. Translocation, Genetic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871391.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Tanaka H, Sasayama T, Nishihara M, Arai A, Kawamura A, Kanomata N, Itoh T, Kohmura E: Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. Neurol Med Chir (Tokyo); 2010;50(8):689-93
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
  • A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting.
  • Magnetic resonance (MR) imaging demonstrated multiple tumors in the brain, subcutaneous soft tissue, and mediastinum.
  • The histological diagnosis was undifferentiated high-grade sarcoma.
  • Promoter hypermethylation in the O(6)-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) genes was detected and MGMT protein expression was negative in the recurrent tumor, so temozolomide (TMZ) salvage chemotherapy was given, and follow-up MR imaging showed tumor reduction.
  • This case suggests that TMZ may be effective for brain metastasis of undifferentiated sarcoma without MGMT protein expression.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Female. Gene Silencing. Humans. Salvage Therapy. Soft Tissue Neoplasms / enzymology. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / therapy. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805657.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


70. Lin J, Wang J, Yu LJ, Ying XL: [Low-grade fibromyxoid sarcoma: a clinicopathological analysis of 9 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 May;38(5):302-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-grade fibromyxoid sarcoma: a clinicopathological analysis of 9 cases].
  • OBJECTIVE: To study the clinicopathological features, immnophenotype and differential diagnosis of low-grade fibromyxoid sarcoma (LGFMS).
  • Three cases presented with recurrent diseases after incomplete resection.
  • CONCLUSIONS: LGFMS is a distinctive low grade fibroblastic sarcoma of young adults.
  • [MeSH-major] Extremities / pathology. Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology. Vimentin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Myxosarcoma / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575871.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


71. Kalra S, Gupta R, Singh S, Gupta K, Kudesia M: Primary cutaneous ewing's sarcoma/primitive neuroectodermal tumor: report of the first case diagnosed on aspiration cytology. Acta Cytol; 2010 Mar-Apr;54(2):193-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous ewing's sarcoma/primitive neuroectodermal tumor: report of the first case diagnosed on aspiration cytology.
  • BACKGROUND: Extraskeletal Ewing's sarcoma (ES) was first recognized as a soft tissue tumor in 1975.
  • Primacy cutaneous occurrence of Ewing's sarcoma/primitive neuroectodermnal tumor (ES/PNET) has been reported in only 31 cases so far.
  • CASE: A young adult presented with a recurrent swelling on the medial aspect of the left leg that had been present for the past 5 years.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / pathology. Sarcoma, Ewing / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / metabolism. Biopsy, Fine-Needle. Cell Adhesion Molecules / metabolism. Humans. Immunohistochemistry. Male. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism. Skin / metabolism. Skin / pathology. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391978.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


72. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A: Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol; 2007 Dec;14(12):3542-51
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution.
  • BACKGROUND: Epithelioid sarcoma (ES) is a rare subtype of soft-tissue sarcoma of unknown histogenesis.
  • Thirty-six patients presented with a primary and 18 with a recurrent tumor.
  • Thirty patients relapsed; in detail, local and distant failure occurred in 14 (25.9%) and 24 (44.4%) patients, respectively.
  • [MeSH-major] Epithelioid Cells / pathology. Sarcoma / mortality. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909905.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Jannasch O, Dombrowski F, Lippert H, Meyer F: Rare coincidence of familial adenomatous polyposis and a retroperitoneal fibromyxoid sarcoma: report of a case. Dis Colon Rectum; 2008 Apr;51(4):477-81
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare coincidence of familial adenomatous polyposis and a retroperitoneal fibromyxoid sarcoma: report of a case.
  • RESULTS: Histopathologic findings after complete tumor resection showed a low-grade fibromyxoid sarcoma.
  • CT scan and clinical follow-up through 15 months postoperatively revealed no recurrent tumor growth.
  • CONCLUSIONS: To our knowledge, this is the first reported case of familial adenomatous polyposis with metachronous retroperitoneal fibromyxoid sarcoma.
  • In addition to more common semimalignant retroperitoneal desmoid tumors in familial adenomatous polyposis patients, a malignant soft-tissue tumor also has to be considered for differential diagnosis.
  • [MeSH-minor] Adult. Anastomosis, Surgical / methods. Colonic Pouches. Colonoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Laparotomy. Male. Proctocolectomy, Restorative / methods. Rectum / surgery. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180996.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Mertens F, Fletcher CD, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, Downs-Kelly E, Fisher C, Goldblum JR, Guillou L, Reid R, Rosai J, Sciot R, Mandahl N, Panagopoulos I: Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest; 2005 Mar;85(3):408-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene.
  • Low-grade fibromyxoid sarcoma (LGFMS) is an indolent, late-metastasizing malignant soft-tissue tumor that is often mistaken for either more benign or more malignant tumor types.
  • Cytogenetic analyses have identified a recurrent balanced translocation t(7;16) (q32-34;p11), later shown by molecular genetic approaches to result in a FUS/CREB3L2 fusion gene.
  • For this purpose, a series of potential LGFMS were obtained from nine different soft-tissue tumor centres and subjected to molecular analysis as well as careful histopathologic review.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 16 / genetics. Chromosomes, Human, Pair 7 / genetics. Fibrosarcoma / genetics. Nerve Tissue Proteins / genetics. RNA-Binding Protein FUS / genetics. Soft Tissue Neoplasms / genetics. Transcription Factors / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Amino Acid Sequence. Base Sequence. Child. Cyclic AMP Response Element-Binding Protein. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Recombinant Fusion Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15640831.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CREB3L1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Nerve Tissue Proteins; 0 / RNA-Binding Protein FUS; 0 / Recombinant Fusion Proteins; 0 / Transcription Factors
  •  go-up   go-down


75. Erzen D, Novak J, Spiler M, Sencar M: Aggressive surgical treatment of retroperitoneal sarcoma: long-term experience of a single institution. Surg Technol Int; 2007;16:97-106
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive surgical treatment of retroperitoneal sarcoma: long-term experience of a single institution.
  • Surgery is the main modality in the therapy of retroperitoneal soft-tissue sarcomas (RSTS).
  • A retrospective study was undertaken to evaluate the results of aggressive surgical treatment in a series of patients of primary and recurrent retroperitoneal sarcomas.
  • The five- and ten-year survival rates of patients with localized sarcoma were 52% and 38%, respectively.
  • When only R0 resection was considered, referral status (primary, residual, recurrent RSTS) influenced survival (p = 0.004).
  • Unless no other treatment modalities are available, aggressive surgery for recurrent sarcoma is recommended.
  • [MeSH-major] Postoperative Complications / surgery. Retroperitoneal Neoplasms / mortality. Retroperitoneal Neoplasms / surgery. Sarcoma / mortality. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Longitudinal Studies. Male. Middle Aged. Risk Assessment / methods. Risk Factors. Slovenia / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429776.001).
  • [ISSN] 1090-3941
  • [Journal-full-title] Surgical technology international
  • [ISO-abbreviation] Surg Technol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Hanna SA, David LA, Gikas PD, Tindall AJ, Cannon SR, Briggs TW: Very late local recurrence of Ewing's sarcoma--can you ever say 'cured'? A report of two cases and literature review. Ann R Coll Surg Engl; 2008 Oct;90(7):W12-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late local recurrence of Ewing's sarcoma--can you ever say 'cured'? A report of two cases and literature review.
  • We report two rare cases of very late local recurrence of Ewing's sarcoma, occurring 16 years and 19 years after treatment of the primary tumour.
  • The two patients were eventually referred back to our institution after the diagnosis of recurrent Ewing's sarcoma was established.
  • [MeSH-major] Bone Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1989 Apr 15;63(8):1477-86 [2924256.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):406-12 [8084307.001]
  • [Cites] Oncologist. 2006 May;11(5):503-19 [16720851.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):603-11 [17177205.001]
  • [Cites] Ann Oncol. 2003 Nov;14(11):1654-9 [14581274.001]
  • [Cites] Med Pediatr Oncol. 2002 Dec;39(6):586-93 [12376982.001]
  • [Cites] Med Pediatr Oncol. 2003 Mar;40(3):141-7 [12518341.001]
  • [Cites] Med Pediatr Oncol. 2003 May;40(5):276-87 [12652615.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):561-9 [11900241.001]
  • (PMID = 18831863.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  • [Other-IDs] NLM/ PMC2728314
  •  go-up   go-down


77. Abe T, Kamida T, Goda M, Inoue R, Fujiki M, Kobayashi H, Hatano Y, Shibuya H, Fujiwara S, Terashi H, Mori T: Intracranial infiltration by recurrent scalp dermatofibrosarcoma protuberans. J Clin Neurosci; 2009 Oct;16(10):1358-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial infiltration by recurrent scalp dermatofibrosarcoma protuberans.
  • Dermatofibrosarcoma protuberans (DFSP) of the scalp is a rare soft tissue sarcoma.
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Radiosurgery / methods. Young Adult

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560926.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


78. Noel KE, Mardirossian G, Schneider L: Primary intraosseous Kaposi's sarcoma presenting as an asymptomatic periapical radiolucency: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May;103(5):e65-70
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraosseous Kaposi's sarcoma presenting as an asymptomatic periapical radiolucency: a case report.
  • Kaposi's sarcoma (KS) is a common mucocutaneous manifestation of acquired immunodeficiency syndrome (AIDS).
  • Excision of the lesion revealed a fleshy, pink-red soft tissue mass with a uniform consistency.
  • One year after surgical procedure, the surgical defect showed radiographic evidence of repair and there was no sign of recurrent tumor.
  • [MeSH-major] HIV Infections / complications. Mandibular Neoplasms / complications. Sarcoma, Kaposi / complications
  • [MeSH-minor] Adult. Fatal Outcome. Herpesvirus 8, Human / isolation & purification. Humans. Immunoenzyme Techniques. Male

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317238.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer; 2008 Jul 15;113(2):419-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
  • METHODS: A retrospective case review of 22 patients with recurrent or refractory bone or soft-tissue sarcomas who received gemcitabine (at a dose of 675 mg/m(2) intravenously on Days 1 and 8) and docetaxel (at a dose of 75-100 mg/m(2) intravenously on Day 8) was undertaken.
  • Seventeen patients had osteosarcoma, 2 patients had Ewing sarcoma family of tumors (ESFT), 1 patient had a malignant fibrous histiocytoma (MFH), 1 patient had a chondrosarcoma, and 1 patient had an undifferentiated sarcoma.
  • CONCLUSIONS: In the current study, gemcitabine in combination with docetaxel was found to be well tolerated and demonstrated antitumor activity in children and adolescents with recurrent or refractory osteosarcoma and MFH.
  • [MeSH-minor] Adolescent. Adult. Child. Dose-Response Relationship, Drug. Female. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18484657.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


80. Bousquet G, Confavreux C, Magné N, de Lara CT, Poortmans P, Senkus E, de Lafontan B, Bolla M, Largillier R, Lagneau E, Kadish S, Lemanski C, Ozsahin M, Belkacémi Y: Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol; 2007 Dec;85(3):355-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network.
  • BACKGROUND AND PURPOSE: Breast sarcoma (BS) is a rare tumour.
  • RESULTS: After a median follow-up of 64 months, 56 patients developed recurrent disease: 38 presented a local relapse and 37 developed distant metastases.
  • CONCLUSION: While angiosarcoma has the worst prognosis, the outcome of the other types of sarcomas may be worsened by residual tumour after loco-regional treatment and high grade histology, a classical prognostic factor of the other soft tissue sarcomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023492.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


81. Leibl S, Moinfar F: Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. Am J Surg Pathol; 2006 Apr;30(4):450-6
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation.
  • We present an extensive immunohistochemical analysis of 7 mammary sarcomas that did not fit into any specific soft tissue sarcoma category.
  • Other myoepithelial markers and steroid receptors were absent, except androgen receptors, which were expressed in one sarcoma.
  • The distinction of specific, histogenetically defined sarcoma entities (such as leiomyosarcoma, angiosarcoma, liposarcoma) from NOS-type sarcoma with CD10 expression is usually clear-cut because the former exhibit a characteristic histomorphology and immunoprofile.
  • Phyllodes tumors with stromal overgrowth or recurrent phyllodes tumors lacking epithelial structures as well as periductal stromal sarcomas can be ruled out by their frequent expression of CD34 and negativity for myoepithelial markers.
  • The immunophenotype of NOS-type sarcomas with CD10 expression suggests that these neoplasms represent a mammary sarcoma variant with myoepithelial features.
  • [MeSH-major] Breast Neoplasms / pathology. Myoepithelioma / pathology. Neprilysin / metabolism. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinosarcoma / diagnosis. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged


82. Park JO, Qin LX, Prete FP, Antonescu C, Brennan MF, Singer S: Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. Ann Surg; 2009 Dec;250(6):977-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule.
  • OBJECTIVE: To identify the prognostic variables that predict disease-specific survival and second local recurrence-free survival in patients with recurrent retroperitoneal liposarcoma so as to guide clinical management.
  • METHODS: From a prospective sarcoma database we selected 105 patients who had at least one local recurrence following complete resection of a primary retroperitoneal liposarcoma between July 1982 and December 2005.
  • CONCLUSIONS: Local recurrence growth rate is strongly associated with disease-specific survival and local control for patients with completely resected locally recurrent retroperitoneal liposarcoma.

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1637-43 [10764423.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:32-40 [18434637.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):359-68 [11466691.001]
  • [Cites] J Am Coll Surg. 2001 Oct;193(4):373-9 [11584964.001]
  • [Cites] Stat Med. 2003 Feb 28;22(4):559-71 [12590414.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1 [14501502.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2448-55 [15160351.001]
  • [Cites] Ann Surg. 1984 Aug;200(2):200-4 [6465975.001]
  • [Cites] Ann Surg. 1990 Jul;212(1):51-9 [2363604.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):623-30 [8579124.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):523-8 [10088622.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):381-91 [16926564.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):234-8 [17081725.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4 Suppl):S90-5 [17916527.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:1-3 [18434630.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):555-60 [11169938.001]
  • (PMID = 19953716.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA047179-17; United States / NCI NIH HHS / CA / P01CA47179
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS344379; NLM/ PMC3248745
  •  go-up   go-down


83. Kuttesch JF Jr, Krailo MD, Madden T, Johansen M, Bleyer A, Children's Oncology Group: Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. Pediatr Blood Cancer; 2009 Oct;53(4):590-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.
  • BACKGROUND: A Phase II trial was developed to determine the efficacy and toxicity of intravenous vinorelbine, a semi-synthetic vinca alkaloid, in children, adolescent, and young adults with recurrent or refractory solid malignancies.
  • PROCEDURES: Fifty patients were enrolled among three strata: soft tissue sarcomas [rhabdomyosarcoma (RMS), non-rhabdomyosarcoma, primitive neuroepithelial tumor] (20 patients); brain tumors [astrocytoma (4 patients), medulloblastoma (2 patients), other (16 patients)] (22 patients); neuroblastoma (8 patients).
  • Four responses (one complete, three partial) occurred within the soft tissue sarcoma strata (all with RMS) and two occurred in the brain tumor group (medulloblastoma and astrocytoma).
  • CONCLUSION: Vinorelbine at dose of 30 mg/m(2) can be safely administered to children with recurrent or refractory solid malignancies.
  • The study design identified vinorelbine to be active in the sarcoma category, with a response rate of 36% (4/11) among RMS patients.


84. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer; 2005 Apr 1;103(7):1431-8
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
  • Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma.
  • Arm B accrued patients with other types of soft tissue sarcomas.
  • CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Boronic Acids / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nervous System Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


85. Postovsky S, Barzilai M, Meller I, Kollander Y, Futerman B, Ben Arush MW: Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience. J Pediatr Hematol Oncol; 2008 Mar;30(3):189-95
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience.
  • This study was undertaken to evaluate whether regular follow-up improves overall survival of children with recurrent sarcomas.
  • The medical charts of 107 children diagnosed with soft tissue and bone sarcomas were reviewed, of whom 29 relapsed.
  • (3) other diagnostic and treatment approaches are needed to improve the survival of children with recurrent sarcomas.
  • [MeSH-major] Bone Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Oncology Service, Hospital / statistics & numerical data. Outcome Assessment (Health Care) / statistics & numerical data. Sarcoma / mortality. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Examination. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Israel. Magnetic Resonance Imaging. Male. Positron-Emission Tomography. Predictive Value of Tests. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Survival Rate. Time. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376279.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Savar A, Trent J, Al-Zubidi N, Huh W, Anderson P, Shinder R, Esmaeli B: Efficacy of adjuvant and neoadjuvant therapies for adult orbital sarcomas. Ophthal Plast Reconstr Surg; 2010 May-Jun;26(3):185-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of adjuvant and neoadjuvant therapies for adult orbital sarcomas.
  • PURPOSE: To report a series of adults with orbital soft tissue sarcoma treated with various combinations of chemotherapy, radiation therapy, and surgery and to report on the efficacy of neoadjuvant therapy in these patients.
  • METHODS: The medical records of adults who presented to our institution with orbital soft tissue sarcoma between 2003 and 2008 were reviewed.
  • Nine had primary orbital lesions, 1 had a locally recurrent orbital lesion, 1 had a secondary tumor extending from the paranasal sinuses, and 2 had metastases in the orbit from primary tumors at other sites.
  • Multidisciplinary care with involvement of medical oncologists and radiation oncologists who are familiar with sarcoma chemotherapy and radiation may benefit these patients.
  • [MeSH-major] Chemotherapy, Adjuvant. Neoadjuvant Therapy. Orbital Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Ophthalmologic Surgical Procedures. Radiotherapy. Survival Rate. Treatment Outcome. Visual Acuity / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthal Plast Reconstr Surg. 2011 Mar-Apr;27(2):142; author reply 142-3 [20966791.001]
  • (PMID = 20489544.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Bölke E, Ruf L, Budach W, Reinecke P, Röhrborn A, Pape H, Schwarz A, Schmitt G, Aul C: Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma. Wien Klin Wochenschr; 2005 Dec;117(23-24):833-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma created from fibroblast cells and characterized by a high rate of metastasis or recurrence with poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Histiocytoma, Malignant Fibrous / therapy. Radiotherapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Thoracic Surgery. Transplantation, Autologous. Treatment Outcome


88. Santaella Y, Borrego I, López J, Ortiz MJ, Vázquez R: [18-FDG-PET in a case of recurrent malignant schwannoma]. Rev Esp Med Nucl; 2005 Mar-Apr;24(2):127-30
Genetic Alliance. consumer health - Schwannoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-FDG-PET in a case of recurrent malignant schwannoma].
  • The peripheral nerve sarcoma, also called malignant schwannoma, is originally a soft tissue sarcoma.
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15745683.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


89. Manduch M, Oliveira AM, Nascimento AG, Folpe AL: Massive localised lymphoedema: a clinicopathological study of 22 cases and review of the literature. J Clin Pathol; 2009 Sep;62(9):808-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 22 morbidly obese adults (mean patient weight 186 kg) presented with unilateral, large soft tissue lesions of longstanding duration.
  • Clinically, most lesions were regarded as representing benign processes, including pedunculated lipoma, lymphocoele or recurrent cellulites, although soft tissue sarcoma was also suspected in two cases.
  • [MeSH-minor] Adult. Aged. Cellulitis / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Leg / pathology. Lipoma / diagnosis. Lymphocele / diagnosis. Male. Middle Aged. Obesity, Morbid / complications. Retrospective Studies. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734477.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


90. Akan M, Eker Uluçay G, Kargi B, Yildirim S, Aköz T: Combined reconstruction of complex defects of the chest wall. Scand J Plast Reconstr Surg Hand Surg; 2006;40(2):93-100
Hazardous Substances Data Bank. Methyl methacrylate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three had had recurrent breast carcinoma, seven relapse after excision of a sarcoma, two had had lesions of the chest wall after irradiation, and one had a sternal fistula.
  • Local skin, musculocutaneous and free latissimus dorsi and anterolateral thigh flaps were done to cover soft tissue.
  • The use of Marlex mesh-methylmethacrylate sandwich prostheses for the stabilisation of the skeleton and local musculocutaneous flaps for covering soft tissues after resection of three or more ribs is effective.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537256.001).
  • [ISSN] 0284-4311
  • [Journal-full-title] Scandinavian journal of plastic and reconstructive surgery and hand surgery
  • [ISO-abbreviation] Scand J Plast Reconstr Surg Hand Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Polypropylenes; 196OC77688 / Methylmethacrylate
  •  go-up   go-down


91. Rickelt J, Hoekstra H, van Coevorden F, de Vreeze R, Verhoef C, van Geel AN: Forequarter amputation for malignancy. Br J Surg; 2009 Jul;96(7):792-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent diagnoses were soft-tissue sarcoma (28 patients) and recurrent breast cancer (five).
  • The 5-year overall and disease-free survival for soft-tissue sarcoma was 41 and 26 per cent respectively.
  • CONCLUSION: In locoregional disease such as sarcoma, FQA may offer the only possibility of cure.
  • [MeSH-major] Amputation / methods. Breast Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Arm. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / etiology. Shoulder. Thoracic Wall. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Journal of Surgery Society Ltd.
  • (PMID = 19526625.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, Steinau HU: MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients. Langenbecks Arch Surg; 2009 Mar;394(2):313-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Undifferentiated pleomorphic sarcoma/NOS (not otherwise specified; former pleomorphic and storiform MFH) of the extremities is a common malignant soft tissue tumor in adults.
  • METHODS: From 1996 to 2004, 140 undifferentiated pleomorphic sarcomas/NOS were identified out of 1,200 soft tissue sarcomas of the extremities that were treated at our institution and recorded in a prospective database.
  • All tumors were retrospectively analyzed regarding prognostic factors of the disease, including patient's background (primary or recurrent), histological grade (G2/G3), adjuvant chemotherapy and radiotherapy, size (T1-2) and depth of the tumor, and surgical margins (R0, R1, R2).
  • There was a significant difference between the group presenting with primary tumors (5-year survival: 84%, p < 0.05) and recurrent tumors (5-year survival: 62%, p < 0.05).
  • Prognosis for patients with undifferentiated pleomorphic sarcoma of the extremities depends predominantly on adequate wide resection of the primary tumor.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584203.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Folk GS, Williams SB, Foss RB, Fanburg-Smith JC: Oral and maxillofacial sclerosing epithelioid fibrosarcoma: report of five cases. Head Neck Pathol; 2007 Sep;1(1):13-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing epithelioid fibrosarcoma (SEF) has distinctive morphology and occurs mainly in deep soft tissue of adult extremities.
  • Inclusion required OMFR location, an abundantly sclerotic sarcoma with epithelioid features, and lack of other phenotype by immunohistochemistry.
  • Tumor location included the infra-temporal fossa, buccal mucosa (recurrence extending into bone), anterior mandible (intraosseous primary, focally extending into soft tissue), and left parotid and submandibular gland (with metaplastic bone) regions.
  • One case had no recurrent/residual disease at 3 months.
  • OMFRSEF occur in adults in various locations, but with a common propensity to involve bone; there is recurrent potential and morbidity with higher grade lesions.
  • [MeSH-major] Facial Bones / pathology. Fibrosarcoma / pathology. Maxilla / pathology. Mouth Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Apoptosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Female. Histiocytoma, Benign Fibrous / diagnosis. Humans. Leiomyoma / diagnosis. Male. Middle Aged. Sclerosis. Solitary Fibrous Tumors / diagnosis. Young Adult

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):127-31 [10867148.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):925-31 [2545330.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):699-709 [11395547.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):227-30 [12232581.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):90-4 [14693846.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 15;152(2):136-40 [15262433.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):410-3 [15322876.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):956-9; discussion 959-60 [11014436.001]
  • [Cites] Methods Enzymol. 1990;184:357-63 [1697021.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):979-93 [7661286.001]
  • [Cites] Histopathology. 1996 May;28(5):451-5 [8735721.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Histopathology. 1998 Oct;33(4):354-60 [9822926.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Dec;107(2):102-6 [9844602.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 Feb;114(2):87-9 [15757185.001]
  • [ErratumIn] Head Neck Pathol. 2013 Mar;7(1):103
  • (PMID = 20614275.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807507
  • [Keywords] NOTNLM ; Maxillofacial / Oral / Sarcoma / Sclerosing epithelioid fibrosarcoma
  •  go-up   go-down


94. Dziewirski W, Rutkowski P, Nowecki ZI, Sałamacha M, Morysiński T, Kulik A, Kawczyńska M, Kasprowicz A, Lyczek J, Ruka W: Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. Ann Surg Oncol; 2006 Feb;13(2):245-52
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study was to analyze the results of treatment of retroperitoneal soft tissue sarcomas (RSTS) by surgery combined with intraoperative brachytherapy (IOBRT).
  • METHODS: Seventy adult patients with RSTS were considered for combined treatment (surgery plus IOBRT) between June 1998 and February 2004.
  • There were 64 (91%) recurrent tumors, and 93% of tumors exceeded 5 cm.
  • [MeSH-major] Brachytherapy. Neoplasm Recurrence, Local / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Intraoperative Care. Male. Middle Aged. Poland / epidemiology. Prognosis. Radiotherapy Dosage. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16411144.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Eyesan SU, Obalum DC, Onovo DO, Ketiku KK, Abdulkareem FB: Clinico-pathologic patterns of extremity liposarcoma. Niger Postgrad Med J; 2010 Mar;17(1):27-9
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Liposarcoma accounted for 6 [27.3%] of 22 cases of soft tissue sarcomas seen within the study period.
  • Survival and recurrent rates could not be determined as all patients were lost to follow-up soon after surgery.
  • CONCLUSION: Liposarcoma is the commonest extremity soft tissue sarcoma seen in our centre, the myxoid type being the commonest histologic subtype.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Extremities. Follow-Up Studies. Hospitals, Special. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria. Orthopedics. Prospective Studies. Radiotherapy, Adjuvant. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348979.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


96. Nilbert M, Therkildsen C, Nissen A, Akerman M, Bernstein I: Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. Fam Cancer; 2009;8(3):209-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age at sarcoma diagnosis was 43 (15-74) years.
  • Soft tissue sarcomas predominated followed by uterine sarcomas and eight histopathological subtypes were represented with recurrent diagnoses of liposarcoma, leiomyosarcoma, and carcinosarcoma.
  • Tumor tissue from eight cases was available for analysis of mismatch-repair (MMR) status using immunohistochemical staining and analysis of microsatellite instability, which revealed MMR defects in six of the eight tumors investigated.
  • This suggests that sarcomas may be part of the HNPCC tumor spectrum and that colorectal cancer should be considered in the family history of sarcoma patients.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. MutS Homolog 2 Protein / genetics. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Colorectal Neoplasms / genetics. DNA Mismatch Repair. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics. Endometrial Neoplasms / genetics. Female. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130300.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


97. Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, Tsuji H, Ito H, Tsujii H: Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1105-10
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the applicability of carbon ion radiotherapy (CIRT) for unresectable retroperitoneal sarcomas with regard to normal tissue morbidity and local tumor control.
  • METHODS AND MATERIALS: From May 1997 to February 2006, 24 patients (17 male and 7 female) with unresectable retroperitoneal sarcoma received CIRT.
  • Of the patients, 16 had primary disease and 8 recurrent disease.
  • [MeSH-major] Carbon Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy. Retroperitoneal Neoplasms / radiotherapy. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon. Female. Follow-Up Studies. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Radiodermatitis / pathology. Radiotherapy Dosage. Relative Biological Effectiveness. Survival Rate. Tomography, X-Ray Computed. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467578.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 7440-44-0 / Carbon
  •  go-up   go-down


98. Idbaih A, Coindre JM, Derré J, Mariani O, Terrier P, Ranchère D, Mairal A, Aurias A: Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest; 2005 Feb;85(2):176-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma.
  • Losses found in the chromosomal arms 1q, 2q, 3p, 4q, 10q, 11q and 13q were also recurrent.
  • Moreover, pLPS-mMFH represented, according to the clustering software results, an entity clearly distinguished from other soft tissue sarcomas, LMS in particular, with which they share common genetic aberrations.
  • The characterization of common gene alterations in both tumor groups would suggest a closer relationship between these two types of soft tissue sarcomas.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human. Histiocytoma, Benign Fibrous / genetics. Liposarcoma / genetics. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Mapping. Female. Humans. In Situ Hybridization. Karyotyping. Male. Middle Aged


99. Bestic JM, Peterson JJ, Bancroft LW: Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected]. Radiographics; 2009 Sep-Oct;29(5):1487-500
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing sarcoma family tumors account for approximately 3% of all pediatric cancers, making them the second most common bone malignancies in children and adolescents.
  • Advances in the treatment of localized disease have dramatically prolonged the survival of patients in whom Ewing sarcoma is diagnosed, but the prognosis for patients with metastatic or recurrent disease remains poor.
  • Radiologic evaluation of Ewing sarcoma can help (a) detect and accurately assess the extent of disease prior to treatment, (b) determine whether metastatic or recurrent disease is present, and (c) monitor therapy response.
  • Standard imaging evaluation of bone and soft-tissue sarcomas typically consists of conventional radiography, magnetic resonance (MR) imaging, computed tomography (CT), and bone scintigraphy.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Bone Neoplasms / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Sarcoma, Ewing / radionuclide imaging. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Neoplasm Staging. Prognosis. Radiopharmaceuticals. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • [CommentIn] Radiographics. 2009 Sep-Oct;29(5):1500-1; discussion 1501 [19764110.001]
  • [ErratumIn] Radiographics. 2010 Jan-Feb;30(1):301
  • (PMID = 19755607.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 21
  •  go-up   go-down


100. Kneser U, Bach AD, Polykandriotis E, Kopp J, Horch RE: Delayed reverse sural flap for staged reconstruction of the foot and lower leg. Plast Reconstr Surg; 2005 Dec;116(7):1910-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Soft-tissue defects of the foot and lower leg caused by traumatic injury, tumor ablation, or infection associated with osteomyelitis often require coverage by flaps.
  • METHODS: The authors successfully used delayed sural flaps based on a two-step procedure for the treatment of 11 patients (three women and eight men, age 50.1 +/- 20.0 years) with osteomyelitis (n = 3), melanoma (n = 3), sarcoma (n = 1), squamous cell carcinoma (n = 1), posttraumatic defects (n = 2), and recurrent gouty ulcer (n = 1).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chronic Disease. Debridement. Female. Heel / surgery. Humans. Male. Middle Aged. Skin Transplantation. Soft Tissue Injuries / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Foot Health.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2006 Aug;118(2):571-2 [16874261.001]
  • [CommentIn] Plast Reconstr Surg. 2006 Aug;118(2):572; author reply 572-3 [16874263.001]
  • (PMID = 16327603.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement